Navigation Links
Pivotal study for PSD502 -- the first potential treatment for premature ejaculation
Date:11/19/2009

ATLANTA / SAN DIEGO (November 19, 2009) At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Results of the double-blind treatment phase of this study, which enrolled patients from the U.S., Canada and Poland, are consistent with previously reported results of the pivotal trial conducted in Europe and showed that men who were treated with PSD502 five minutes before intercourse were able to delay ejaculation up to five times longer than those who used placebo. Additionally, patients and partners in both trials reported significant improvements in sexual satisfaction, and the drug was well tolerated.

An estimated one-third of U.S. men ages 18 - 59 are affected by PE, making it twice as prevalent as erectile dysfunction. Currently, there are no prescription therapies approved in the U.S. to treat PE.

PSD502, a product in development for the treatment of PE, is a proprietary formulation of the two marketed drugs lidocaine and prilocaine dispensed by a metered dose aerosol. PSD502 works selectively on non-keratinized skin on the glans penis (head of the penis).

"Premature ejaculation can have a powerful negative impact on the emotional and sexual lives of men and their partners," said Professor Stanley E. Althof, PhD, Center for Marital and Sexual Health of South Florida, West Palm Beach, Florida. "Recently, the international sexual health community agreed that PE should be defined as ejaculation occurring within approximately one minute of penetration that causes the patient distress. Now we need to work to develop treatments, and these encouraging results with PSD502 seem to be a step in the right direction."


'/>"/>

Contact: Dave Schemelia
dschemelia@healthstarpr.com
609-468-9325
HealthStar PR
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
3. Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
4. QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
5. Pivotal White Paper Examines Retail Industrys Critical Role in Reengineering the Health Care System
6. Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
7. Ambulatory Surgery Centers Pivotal in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings
8. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
9. Pivotal Data on Bronchial Thermoplasty from the Asthma Intervention Research 2 (AIR2) Trial to be Presented at ATS 2009
10. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
11. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... May 24, 2015 EnviroLeather™ by ... “InkGard™ Plus” – a classic, rugged leather grain ... allowing difficult stains, including ink, to be easily ... colors suitable for corporate, healthcare, hospitality and education ... with EnviroLeather’s goal of developing products that are ...
(Date:5/24/2015)... Viejo, CA (PRWEB) May 24, 2015 ProPin ... use in Final Cut Pro X. Utilize ProPin to pin ... in a given scene. , ProPin allows users to ... completely customizable in FCPX. With on-screen controls, video editors can ... allows users to pin and mark with absolute ease. , Using ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Krihak as its head of programmatic strategy and ... expertise and leadership position in the data driven ... , Krihak is an experienced, award-winning agency and ... sales planning teams for mobile platform Jumptap. ...
(Date:5/24/2015)... 24, 2015 A report out ... the single best option for avoiding cardiovascular disease is ... level was the single most powerful predictor of death ... as diabetes and family history of premature death -- ... heart and lung fitness. , The Importance of Cardiovascular ...
(Date:5/23/2015)... D.C. (PRWEB) May 23, 2015 On ... of powers of a youngster's yogic power learned through ... Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, a ... more than 50 high profile professionals attending the 2015 ... by reading fluently -- blindfolded. , In a ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... 2009, Cambridge, UK ,Anyone with a sweet tooth knows ... negative consequences. The same can be said about the ... new study of myelin, a protein key to efficient neuronal ... much like the insulation on a cable, allows for rapid ...
... nanospheres equipped with a targeting peptide find melanoma cells, penetrate ... near-infrared light, a research team led by scientists at The ... the Feb. 1 issue of Clinical Cancer Research . ... grail of therapeutic nanotechnology for cancer. We,re getting closer to ...
... Knowing what to expect before and after procedure aids healing, ... With increasing numbers of baby boomers reaching retirement age, joint ... , But improved movement and lack of pain in ... to expect from the surgery and subsequent physical therapy can ...
... Total Health Center shows that our new Hgh product destroys fat cells ... , ... (PRWEB) February 1, 2009 -- Scientists at The Total Health and ... to destroy fat on men and women without dieting. Sources at the ...
... A study in the Feb. 1 issue of the ... levels that occurs during pregnancy is more pronounced in pregnant ... , During the last trimester of pregnancy, levels ... women with RLS and 25,475 pg/mL in healthy controls. ...
... A study in the Feb. 1 issue of the ... associated with changes in the levels of specific cytokines ... suggest that inflammation may be the pathway linking extreme ... Each additional hour of self-reported sleep duration was associated ...
Cached Medicine News:Health News:Targeted nanospheres find, penetrate, then fuel burning of melanoma 2Health News:Targeted nanospheres find, penetrate, then fuel burning of melanoma 3Health News:A Checklist for Joint Replacement Surgery 2Health News:Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome 2Health News:Study suggests that inflammation may be the link between extreme sleep durations and poor health 2
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Milestone Scientific Inc. (OTCQB: MLSS), the recognized leader in ... its 2010 year-end results for the 12 months ended ... Commission on Wednesday, March 30, 2011. Milestone,s ... 4, 2011 beginning at 4:15 PM Eastern Daylight Savings ...
... YORK, April 1, 2011 NeoStem, Inc. (NYSE Amex: ... company with operations in the U.S. and China, is today ... activities: Revenues for the year ended December ... 2009.  2010 was the first full year that results for ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2NeoStem Provides Results for 2010 and an Update on Recent Activities 2NeoStem Provides Results for 2010 and an Update on Recent Activities 3NeoStem Provides Results for 2010 and an Update on Recent Activities 4NeoStem Provides Results for 2010 and an Update on Recent Activities 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: